☆ 4.6 Article

Anti-PD-1 therapy achieves favorable outcomes in HBV-positive non-liver cancer

ONCOGENESIS (2023)

Related references

Note: Only part of the references are listed.

Article Gastroenterology & Hepatology

Single-cell RNA sequencing reveals intrahepatic and peripheral immune characteristics related to disease phases in HBV-infected patients

Chao Zhang et al.

Summary: In this study, the comprehensive immune responses in different phases of HBV infection were analyzed using single-cell RNA sequencing. The results showed that both immune active and acute recovery phases were characterized by high levels of exhausted CD8+ T cells in the liver. Significant cell-cell interactions were observed between these exhausted T cells and regulatory CD4+ T cells, as well as between T cells and macrophages. Specific subsets of CD8+ T cells were expanded during the acute recovery phase, providing a potential marker for viral resolution. This study provides important insights into the immunopathogenesis of HBV and the development of effective therapeutic strategies.

GUT (2023)

Add to Collection

Article Oncology

Hepatotoxicity associated with PD-1 blockade antibodies in cancer patients co-infected with hepatitis B virus

Zuan Lin et al.

Summary: This study found that cancer patients infected with hepatitis B virus are at an increased risk of hepatotoxicity when undergoing PD-1 antibody therapy. Factors such as liver involvement, HBsAg positivity, and baseline HBV DNA levels may be associated with the development of hepatotoxicity. Prophylactic antiviral therapy could decrease the risk of severe hepatotoxicity in these patients.

CANCER IMMUNOLOGY IMMUNOTHERAPY (2022)

Add to Collection

Article Immunology

Reinvestigation of Classic T Cell Subsets and Identification of Novel Cell Subpopulations by Single-Cell RNA Sequencing

Xuefei Wang et al.

Summary: Classic T cell subsets are defined by cell surface markers, while single-cell RNA sequencing clusters cells based on gene expression profiles. Multiple T cell subsets can be assigned to one cluster with similar expression patterns. Higher levels of ISAGs may contribute to quick immune responses.

JOURNAL OF IMMUNOLOGY (2022)

Add to Collection

Article Gastroenterology & Hepatology

Risk of Hepatitis B Virus Reactivation in Patients Treated With Immunotherapy for Anti-cancer Treatment

Sun Yoo et al.

Summary: This study evaluated the risk of hepatitis B virus (HBV) reactivation in cancer patients receiving immune checkpoint inhibitors (ICIs). The results showed that HBV reactivation was rarely observed in patients receiving long-term antiviral prophylaxis. However, HBV reactivation may occur in HBsAg-positive patients without antiviral prophylaxis or noncompliant with antiviral prophylaxis.

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2022)

Add to Collection

Article Gastroenterology & Hepatology

Comparative Safety, Efficacy and Survival Outcome of Anti-PD-1 Immunotherapy in Colorectal Cancer Patients With vs Without Hepatitis B Virus Infection: A Multicenter Cohort Study

Yi-Kan Cheng et al.

Summary: The safety, efficacy, and survival outcome of anti-PD-1 therapy in colorectal cancer (CRC) patients with and without hepatitis B virus (HBV) infection were compared in this retrospective cohort study. After propensity score-matched analysis, the incidences of immune-related adverse events were similar between HBV and non-HBV groups. The overall response rate and survival rates were also comparable between the two groups.

CLINICAL AND TRANSLATIONAL GASTROENTEROLOGY (2022)

Add to Collection

Article Oncology

Efficacy and Safety of PD-1 Immune Checkpoint Inhibitors in Locally Advanced and Advanced Non-Small-Cell Lung Cancer Patients with Chronic Infection

Zhiting Zhao et al.

Summary: This study investigated the efficacy and safety of immune checkpoint inhibitors in non-small-cell lung cancer (NSCLC) patients with chronic infection. The results showed that PD-1 inhibitors had moderate efficacy and an acceptable toxicity profile in these patients, but there was a potential increase in the incidence of hepatitis.

ONCOLOGY RESEARCH AND TREATMENT (2022)

Add to Collection

Article Oncology

Pembrolizumab for locally advanced and recurrent/metastatic cutaneous squamous cell carcinoma (KEYNOTE-629 study): an open-label, nonrandomized, multicenter, phase II trial

B. G. M. Hughes et al.

Summary: The study confirmed the robust anti-tumor activity of pembrolizumab in both locally advanced and recurrent/metastatic cutaneous squamous cell carcinoma patients, showing durable efficacy without unexpected safety signals. Pembrolizumab may be a promising treatment option for these patients.

ANNALS OF ONCOLOGY (2021)

Add to Collection

Article Gastroenterology & Hepatology

Cancer and the Microbiome-Influence of the Commensal Microbiota on Cancer, Immune Responses, and Immunotherapy

Vyara Matson et al.

Summary: The commensal microbiota plays a role in regulating various physiological processes, including affecting cancer immunotherapy either positively or negatively. Studies have shown that different microbes may have distinct impacts on immunotherapy efficacy, leading to clinical trials and microbiome-based therapeutic interventions.

GASTROENTEROLOGY (2021)

Add to Collection

Article Cell Biology

Integrated decoding hematopoiesis and leukemogenesis using single-cell sequencing and its medical implication

Pengfei Qin et al.

Summary: Single-cell RNA sequencing technology was used to analyze the relationship between hematopoiesis and leukemogenesis, revealing different healthy counterparts for leukemia cell subpopulations in different patients and providing insights into the origin of leukemia heterogeneity. The study also developed a framework to predict leukemia subtypes, cellular heterogeneity, and cellular stemness, offering new directions for leukemia research and treatment.

CELL DISCOVERY (2021)

Add to Collection

Article Medicine, General & Internal

Hepatitis B virus infection does not affect the clinical outcome of anti-programmed death receptor-1 therapy in advanced solid malignancies Real-world evidence from a retrospective study using propensity score matching

Liting Zhong et al.

Summary: This study found that HBV infection did not significantly impact the therapy response or prognosis of patients treated with PD-1 inhibitors. Propensity score matching did not reveal any significant differences in objective response rate and disease control rate between HBV and non-HBV groups. Further prospective studies are needed to confirm these findings.

MEDICINE (2021)

Add to Collection

Article Multidisciplinary Sciences

T-cell CX3CR1 expression as a dynamic blood-based biomarker of response to immune checkpoint inhibitors

Takayoshi Yamauchi et al.

Summary: Immune checkpoint inhibitors (ICI) have revolutionized cancer treatment but durable response is limited. CX3CR1, a marker of T-cell differentiation, is investigated as a predictor of response to ICI therapy. Treatment with ICI increases the frequency of circulating CX3CR1(+)CD8(+) T cells and correlates with response and survival in patients with non-small cell lung cancer.

NATURE COMMUNICATIONS (2021)

Add to Collection

Article Multidisciplinary Sciences

Integrated single-cell transcriptome analysis reveals heterogeneity of esophageal squamous cell carcinoma microenvironment

Huy Q. Dinh et al.

Summary: This study utilized single-cell RNA sequencing to characterize the heterogeneous microenvironment of ESCC, identifying a tumor-specific subset of CST1(+) myofibroblasts with prognostic values and immunosuppressive features. The analysis of stromal cell types in the ESCC microenvironment provides a rich resource for further understanding of ESCC biology.

NATURE COMMUNICATIONS (2021)

Add to Collection

Article Oncology

Comparison of HBV reactivation between patients with high HBV-DNA and low HBV-DNA loads undergoing PD-1 inhibitor and concurrent antiviral prophylaxis

Min-Ke He et al.

Summary: In patients with hepatocellular carcinoma receiving PD-1 inhibitor and antiviral prophylaxis, high HBV-DNA load does not increase the risk of HBV reactivation.

CANCER IMMUNOLOGY IMMUNOTHERAPY (2021)

Add to Collection

Article Oncology

Phase 1b Study of Sintilimab Plus Anlotinib as First-line Therapy in Patients With Advanced NSCLC

Tianqing Chu et al.

Summary: Although the evidence supporting the combination of immune checkpoint inhibitors and antiangiogenic tyrosine kinase inhibitors in treatment-naive patients with advanced NSCLC is insufficient, this report presented the efficacy and safety of sintilimab combined with anlotinib in a phase 1b trial. The study showed promising results with a high objective response rate and disease control rate, as well as manageable treatment-related adverse events.

JOURNAL OF THORACIC ONCOLOGY (2021)

Add to Collection

Article Oncology

Safety and efficacy of anti-PD-1 inhibitors in Chinese patients with advanced lung cancer and hepatitis B virus infection: a retrospective single-center study

Fei Xu et al.

Summary: The study analyzed the use of anti-PD-1 immunotherapy in patients with HBV infection and advanced lung cancer, indicating that hepatotoxicity should be closely monitored but is generally controllable, and there were no instances of HBV reactivation post-treatment. The overall response rate was 62.5%, with a median progression-free survival of 3 months.

TRANSLATIONAL LUNG CANCER RESEARCH (2021)

Add to Collection

Article Immunology

Targeting regulator of G protein signaling 1 in tumor-specific T cells enhances their trafficking to breast cancer

Di Huang et al.

Summary: Effective tumor control relies on inflammatory helper and cytotoxic T cells. The protein RGS1 negatively regulates effector T cell homing to tumors, leading to tumor immune evasion and decreased patient survival. Targeting RGS1 may offer a new strategy for tumor immunotherapy.

NATURE IMMUNOLOGY (2021)

Add to Collection

Article Oncology

Association of hepatitis B virus infection status with outcomes of non-small cell lung cancer patients undergoing anti-PD-1/PD-L1 therapy

Xuanye Zhang et al.

Summary: This study evaluated the safety and efficacy of anti-PD-(L)1 monotherapy in patients with NSCLC and HBV infection. Patients with CHB showed higher rates of DCB compared to RHB patients, along with longer PFS and OS. This suggests that patients with HBV infection can benefit from immunotherapy with proper monitoring and use of antiviral prophylaxis.

TRANSLATIONAL LUNG CANCER RESEARCH (2021)

Add to Collection

Review Oncology

Immune cells within the tumor microenvironment: Biological functions and roles in cancer immunotherapy

Xu Lei et al.

CANCER LETTERS (2020)

Add to Collection

Article Oncology

Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial

Richard S. Finn et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

Add to Collection

Article Medicine, Research & Experimental

CX3CR1-CD8+ T cells are critical in antitumor efficacy but functionally suppressed in the tumor microenvironment

Takayoshi Yamauchi et al.

JCI INSIGHT (2020)

Add to Collection

Article Multidisciplinary Sciences

Immune suppressive landscape in the human esophageal squamous cell carcinoma microenvironment

Yingxia Zheng et al.

NATURE COMMUNICATIONS (2020)

Add to Collection

Review Immunology

B cells, plasma cells and antibody repertoires in the tumour microenvironment

George Sharonov et al.

NATURE REVIEWS IMMUNOLOGY (2020)

Add to Collection

Article Oncology

Comparison of Efficacy of Pembrolizumab between Epstein-Barr Virus-Positive and -Negative Relapsed or Refractory Non-Hodgkin Lymphomas

Seok-Jin Kim et al.

CANCER RESEARCH AND TREATMENT (2019)

Add to Collection

Article Oncology

Mobilization of CD8+ T Cells via CXCR4 Blockade Facilitates PD-1 Checkpoint Therapy in Human Pancreatic Cancer

Yongwoo David Seo et al.

CLINICAL CANCER RESEARCH (2019)

Add to Collection

Article Biochemistry & Molecular Biology

GEPIA2: an enhanced web server for large-scale expression profiling and interactive analysis

Zefang Tang et al.

NUCLEIC ACIDS RESEARCH (2019)

Add to Collection

Review Oncology

The negative impact of antibiotics on outcomes in cancer patients treated with immunotherapy: a new independent prognostic factor?

A. Elkrief et al.

ANNALS OF ONCOLOGY (2019)

Add to Collection

Article Biochemistry & Molecular Biology

Comprehensive Integration of Single-Cell Data

Tim Stuart et al.

CELL (2019)

Add to Collection

Article Multidisciplinary Sciences

Metascape provides a biologist-oriented resource for the analysis of systems-level datasets

Yingyao Zhou et al.

NATURE COMMUNICATIONS (2019)

Add to Collection

Article Biochemical Research Methods

Fast, sensitive and accurate integration of single-cell data with Harmony

Ilya Korsunsky et al.

NATURE METHODS (2019)

Add to Collection

Article Oncology

Hepatitis B virus reactivation in cancer patients with positive Hepatitis B surface antigen undergoing PD-1 inhibition

Xuanye Zhang et al.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)

Add to Collection

Article Oncology

Prevalence of Hepatitis B Virus, Hepatitis C Virus, and HIV Infection Among Patients With Newly Diagnosed Cancer From Academic and Community Oncology Practices

Scott D. Ramsey et al.

JAMA ONCOLOGY (2019)

Add to Collection

Review Medicine, General & Internal

Chronic Hepatitis B Infection A Review

Lydia S. Y. Tang et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2018)

Add to Collection

Article Oncology

Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial

Andrew X. Zhu et al.

LANCET ONCOLOGY (2018)

Add to Collection

Article Oncology

Safety and efficacy of anti-PD-1 therapy for metastatic melanoma and non-small-cell lung cancer in patients with viral hepatitis: a case series

Anita Kothapalli et al.

MELANOMA RESEARCH (2018)

Add to Collection

Article Biochemistry & Molecular Biology

Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer

Seung Tae Kim et al.

NATURE MEDICINE (2018)

Add to Collection

Article Oncology

Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non-Small-Cell Lung Cancer

Kathryn C. Arbour et al.

JOURNAL OF CLINICAL ONCOLOGY (2018)

Add to Collection

Article Oncology

Anti-PD-1/PD-L1 immunotherapy in patients with solid organ transplant, HIV or hepatitis B/C infection

Martin Tio et al.

EUROPEAN JOURNAL OF CANCER (2018)

Add to Collection

Review Immunology

Immune checkpoint blockade in infectious diseases

Michelle N. Wykes et al.

NATURE REVIEWS IMMUNOLOGY (2018)

Add to Collection

Article Medicine, General & Internal

Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)

Jacob Schachter et al.

LANCET (2017)

Add to Collection

Article Medicine, General & Internal

Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial

Anthony B. El-Khoueiry et al.

LANCET (2017)

Add to Collection

Article Oncology

Nivolumab treatment for oesophageal squamous-cell carcinoma: an open-label, multicentre, phase 2 trial

Toshihiro Kudo et al.

LANCET ONCOLOGY (2017)

Add to Collection

Article Oncology

Safety of immune checkpoint inhibitors in Chinese patients with melanoma

Xizhi Wen et al.

MELANOMA RESEARCH (2016)

Add to Collection

Article Medicine, General & Internal

Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer

Martin Reck et al.

NEW ENGLAND JOURNAL OF MEDICINE (2016)

Add to Collection

Article Oncology

Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial

Jeffrey S. Weber et al.

LANCET ONCOLOGY (2015)

Add to Collection

Article Gastroenterology & Hepatology

Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study

Joong-Won Park et al.

LIVER INTERNATIONAL (2015)

Add to Collection

Review Immunology

Innate and adaptive immune cells in the tumor microenvironment

Thomas F. Gajewski et al.

NATURE IMMUNOLOGY (2013)

Add to Collection

Review Oncology

AP-1: A double-edged sword in tumorigenesis

R Eferl et al.

NATURE REVIEWS CANCER (2003)

Add to Collection

© Peeref 2019-2024. All rights reserved.